Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer

被引:1
|
作者
Kono, Yusuke [1 ]
Matsunaga, Tomoyuki [1 ]
Makinoya, Masahiro [1 ]
Shimizu, Shota [1 ]
Shishido, Yuji [1 ]
Miyatani, Kozo [1 ]
Kihara, Kyoichi [1 ]
Yamamoto, Manabu [1 ]
Takano, Shuichi [1 ]
Tokuyasu, Naruo [1 ]
Sakamoto, Teruhisa [1 ]
Hasegawa, Toshimichi [1 ]
Fujiwara, Yoshiyuki [1 ]
机构
[1] Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol,Fac Med, 36-1 Nishi Cho, Yonago 6838504, Japan
关键词
Gastric cancer; Adjuvant chemotherapy; Sarcopenia; Elderly; S-1; ANAMORELIN;
D O I
10.1007/s00595-023-02737-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and purposeOlder patients are more likely to encounter difficulties receiving chemotherapy, but the factors involved in the continuation of chemotherapy in these patients remain unclear. We investigated the importance of muscle mass as a factor involved in delivering a sufficient dose of postoperative S-1 adjuvant chemotherapy (ACT) to older patients with gastric cancer.MethodsThe subjects of this study were 79 patients aged & GE; 65 years with stage II/III gastric adenocarcinoma, who underwent curative gastrectomy and received S-1 ACT.ResultsThe overall median relative dose intensity (RDI) was 75.0% (18.8-93.5%). Patients were divided into two groups for receiver operating characteristic analysis according to the cutoff value. Significantly more patients in the high skeletal muscle index (SMI) group achieved > 62% RDI of S-1 ACT (p = 0.03). Conversely, more patients in the low SMI group suffered from S-1-induced nausea (p = 0.03) and discontinued chemotherapy because of adverse events (p = 0.02). Multivariate analysis identified low SMI as an independent factor for insufficient S-1 dose delivery (p = 0.03, hazard ratio = 2.87).ConclusionPreoperative SMI is an indicator of the low-dose intensity of S-1 ACT in older patients following curative gastrectomy.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 50 条
  • [31] A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03
    Okabe, Hiroshi
    Hata, Hiroaki
    Ueda, Shugo
    Zaima, Masazumi
    Tokuka, Atsuo
    Yoshimura, Tsunehiro
    Ota, Shuichi
    Kinjo, Yousuke
    Yoshimura, Kenichi
    Sakai, Yoshiharu
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (01) : 36 - 41
  • [32] Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists
    Kano, Yosuke
    Ohashi, Manabu
    Hiki, Naoki
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    Ida, Satoshi
    Kumagai, Koshi
    Sano, Takeshi
    Nunobe, Souya
    SURGERY TODAY, 2020, 50 (10) : 1197 - 1205
  • [33] Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer
    Kochi, Mitsugu
    Fuji, Masashi
    Kanamori, Noriaki
    Mihara, Yoshiaki
    Funada, Tomoya
    Tamegai, Hidenori
    Watanabe, Megumu
    Takayama, Yuriko
    Suda, Hiroshi
    Takayama, Tadatoshi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 17 - 21
  • [34] Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists
    Yosuke Kano
    Manabu Ohashi
    Naoki Hiki
    Daisuke Takahari
    Keisho Chin
    Kensei Yamaguchi
    Satoshi Ida
    Koshi Kumagai
    Takeshi Sano
    Souya Nunobe
    Surgery Today, 2020, 50 : 1197 - 1205
  • [35] Adjuvant chemotherapy may have no significant survival benefit in older patients with stage II/III gastric cancer: a multicenter retrospective study
    Zheng-Zheng Shen
    En-Ze Li
    Ruo-Lan Zhang
    Meng-Xuan Cao
    Yan-Qiang Zhang
    Qing Yang
    Can Hu
    Si-Wei Pan
    Zhi-Yuan Xu
    Zai-Sheng Ye
    Jing-Yang He
    Journal of Cancer Research and Clinical Oncology, 151 (5)
  • [36] Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1
    Aoyama, Toru
    Yoshikawa, Takaki
    Watanabe, Takafumi
    Hayashi, Tsutomu
    Ogata, Takashi
    Cho, Haruhiko
    Tsuburaya, Akira
    GASTRIC CANCER, 2011, 14 (03) : 274 - 278
  • [37] Feasibility and predictive factors on the completion of docetaxel plus S-1 adjuvant chemotherapy in pathological stage III gastric cancer
    Terayama, Masayoshi
    Ohashi, Manabu
    Yamaguchi, Kensei
    Takahari, Daisuke
    Makuuchi, Rie
    Hayami, Masaru
    Ida, Satoshi
    Kumagai, Koshi
    Sano, Takeshi
    Nunobe, Souya
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2025, 9 (01): : 60 - 68
  • [38] Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1
    Toru Aoyama
    Takaki Yoshikawa
    Takafumi Watanabe
    Tsutomu Hayashi
    Takashi Ogata
    Haruhiko Cho
    Akira Tsuburaya
    Gastric Cancer, 2011, 14 : 274 - 278
  • [39] Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Miyamoto, Hiroshi
    Sato, Sho
    Tanaka, Yusaku
    Sato, Kei
    Kunisaki, Chikara
    Endo, Itaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1047 - 1055
  • [40] Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy
    Hosoda, Kei
    Yamashita, Keishi
    Ushiku, Hideki
    Ema, Akira
    Moriya, Hiromitsu
    Mieno, Hiroaki
    Washio, Marie
    Watanabe, Masahiko
    ONCOLOGY LETTERS, 2018, 15 (02) : 1853 - 1860